Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ107 (Efineptakin alfa) in Advanced Solid Tumors
NCT04001075Phase 2Completed
- Sponsor
- TJ Biopharma
- Start
- Feb 2019
- Primary completion
- Jun 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efineptakin alfa in solid tumor, sponsored by TJ Biopharma. Started Feb 2019; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04001075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001075.